ImmunityBio (IBRX) Projected to Post Earnings on Tuesday

by · The Cerbat Gem

ImmunityBio (NASDAQ:IBRX – Get Free Report) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $31.8820 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

ImmunityBio (NASDAQ:IBRX – Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). The business had revenue of $26.43 million for the quarter, compared to analysts’ expectations of $21.95 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ImmunityBio Stock Down 2.4%

Shares of IBRX traded down $0.06 on Tuesday, reaching $2.21. The stock had a trading volume of 1,167,824 shares, compared to its average volume of 8,267,713. The firm has a market capitalization of $2.17 billion, a PE ratio of -4.59 and a beta of 0.29. The firm has a 50-day moving average of $2.50 and a 200 day moving average of $2.59. ImmunityBio has a twelve month low of $1.83 and a twelve month high of $5.88.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IBRX. Diversify Advisory Services LLC acquired a new position in ImmunityBio in the second quarter worth about $27,000. Sei Investments Co. acquired a new position in ImmunityBio in the second quarter valued at approximately $31,000. Engineers Gate Manager LP acquired a new position in ImmunityBio in the second quarter valued at approximately $35,000. Tower Research Capital LLC TRC boosted its stake in ImmunityBio by 181.6% in the second quarter. Tower Research Capital LLC TRC now owns 16,922 shares of the company’s stock valued at $45,000 after acquiring an additional 10,912 shares during the period. Finally, Cetera Investment Advisers boosted its stake in ImmunityBio by 56.9% in the second quarter. Cetera Investment Advisers now owns 18,551 shares of the company’s stock valued at $49,000 after acquiring an additional 6,731 shares during the period. 8.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on IBRX. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a report on Wednesday, September 10th. D. Boral Capital reiterated a “buy” rating and set a $24.00 target price on shares of ImmunityBio in a report on Monday, September 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a report on Tuesday, October 14th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, ImmunityBio presently has an average rating of “Moderate Buy” and a consensus price target of $10.75.

Get Our Latest Stock Analysis on ImmunityBio

ImmunityBio Company Profile

(Get Free Report)

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

Featured Stories